In addition, although colchicine seems promising to reduce inflammation and CVD risk, most trials to date excluded patients with CKD because colchicine accumulates in these patients.78 Other trials have focussed on the NLRP3-dependent cytokines, such as the CANTOS (Canakinumab Anti‐Inflammatory Thrombosis Outcomes) trial, which tested a monoclonal antibody, canakinumab, against IL-1β in patients with CVD.79 Thereby, it could be shown that canakinumab also reduced hs-CRP and IL-6, resulting in a reduced risk for cardiovascular death, among others. Here, NLRP3 is linked to chronic kidney disease.